Literature DB >> 9447898

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

D Genné1, H H Siegrist, L Humair, B Janin-Jaquat, A de Torrenté.   

Abstract

In an open, prospective, randomised study, the clinical and bacteriological efficacy of intravenously administered clarithromycin was compared with that of amoxicillin-clavulanic acid in 112 patients with community-acquired pneumonia requiring hospitalisation. Clinical cure or improvement occurred in 86% (48/56) of the clarithromycin-treated patients and 84% (47/56) of the amoxicillin-clavulanic acid-treated patients. The rate of bacteriologic eradication was similar for the two drugs as were the rapidity of a clinical response and the rate of improvement of radiological signs. Clarithromycin had a slightly higher rate of side-effects mainly due to phlebitis caused by the intravenous treatment, but treatment could be continued in all cases. Clarithromycin should be used with caution in patients being treated with digoxin because of a significant risk of bradycardia resulting from drug interaction.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9447898     DOI： 10.1007/BF01700406

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   5.103


  15 in total

1.  Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.

Authors:  G Kinasewitz; R G Wood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 2.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 3.  Sequential therapy in the hospital management of lower respiratory infections.

Authors:  F Vogel
Journal:  Am J Med       Date:  1995-12-29       Impact factor: 4.965

4.  Microbial etiology of acute pneumonia in hospitalized patients.

Authors:  J H Bates; G D Campbell; A L Barron; G A McCracken; P N Morgan; E B Moses; C M Davis
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

5.  In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit.

Authors:  P Moine; J B Vercken; S Chevret; C Chastang; P Gajdos
Journal:  Chest       Date:  1994-05       Impact factor: 9.410

7.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

8.  Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy.

Authors:  S R Weingarten; M S Riedinger; G Varis; M S Noah; M J Belman; R D Meyer; A G Ellrodt
Journal:  Chest       Date:  1994-04       Impact factor: 9.410

9.  Prospective study of the aetiology and outcome of pneumonia in the community.

Authors:  M A Woodhead; J T Macfarlane; J S McCracken; D H Rose; R G Finch
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

Review 10.  Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. The British Thoracic Society.

Authors: 
Journal:  Br J Hosp Med       Date:  1993 Mar 3-16
View more
  10 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

4.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Vesiculobullous eruption of the right arm after intravenous clarithromycin.

Authors:  Abdulkadir Kuçukbayrak; Engin Senel; Zeynep Seckin Kücükbayrak; Ersin Gunay; Ezgi Simsek
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

Review 6.  Community-acquired pneumonia in the elderly: a practical guide to treatment.

Authors:  D Lieberman; D Lieberman
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

7.  [Antibiotic sensitivity of important pathogens of bacterial respiratory tract infections in Northeast Germany].

Authors:  O Fierek; P Hinniger; B Panzig
Journal:  Med Klin (Munich)       Date:  1998-11-15

Review 8.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae.

Authors:  Pablo Bonvehi; Katherine Weber; Todd Busman; Dee Shortridge; Gerard Notario
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 10.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.